Abeona Therapeutics Inc. (NASDAQ: ABEO) is a Healthcare company (Biotechnology) with a market capitalization of $149M. The Maz Rating grades it against the other companies in its sector.
Abeona Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.60, Abeona Therapeutics Inc. trades at 3.8x sales and 1.2x book value. Over the last twelve months it generated about $39M of revenue and a net loss of $65M. It runs a gross margin of 58.2%, an operating margin of -186.1% and a net margin of -160.3%. It shows return on equity of -44.8%, return on invested capital of -46.0% and a free cash flow yield of -44.7%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 5.69. Over the past 52 weeks the share price ranged from $2.09 to $7.65, with a beta of 1.30.
Abeona Therapeutics Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.